Oil prices hold sharp losses with focus on secondary India tariffs
TEL AVIV—Richard Daniell, Executive Vice President of European Commercial at Teva Pharmaceutical (TADAWUL:2070) Industries Ltd. (NYSE:TEVA), recently made significant stock transactions according to a filing with the Securities and Exchange Commission. Over the course of March 4 and March 5, Daniell sold a total of 133,472 ordinary shares, generating approximately $2.2 million. The sales were executed at prices ranging from $15.7346 to $15.9132 per share. The stock, currently trading at $15.36, appears undervalued according to InvestingPro analysis, with analysts setting price targets between $18.07 and $30.
These transactions were part of a pre-established trading plan under Rule 10b5-1, which allows company insiders to set up a predetermined schedule for buying or selling company stock to avoid accusations of insider trading. With a market capitalization of $18.2 billion and a "Fair" financial health score from InvestingPro, Teva remains a prominent player in the pharmaceuticals industry.
Additionally, Daniell exercised options to acquire a total of 237,142 ordinary shares at no cost. Following these transactions, Daniell holds no shares directly under his name, as disclosed in the filing. While currently unprofitable, InvestingPro data indicates analysts expect the company to return to profitability this year, with revenue growth of 3% projected for 2025.
In other recent news, Teva Pharmaceutical Industries Ltd. reported fourth-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $0.71 and revenue of $4.23 billion, surpassing projections of $0.69 per share and $4.1 billion in revenue. Despite this, Teva’s guidance for 2025 fell short, with projected earnings per share of $2.35-$2.65 and revenue of $16.8-17.4 billion, below Wall Street’s estimates. In another development, the U.S. Food and Drug Administration accepted Teva and Medincell’s supplemental application for UZEDY as a treatment for bipolar I disorder, highlighting the potential for this long-acting injectable to address significant barriers in mental health treatment.
Additionally, Teva reached a settlement with Axsome Therapeutics (NASDAQ:AXSM) regarding patent litigation over AUVELITY, allowing Teva to sell a generic version of the drug starting in 2038 or 2039, depending on exclusivity conditions. BofA Securities recently adjusted Teva’s financial outlook, lowering the price target from $23.00 to $20.00 while maintaining a Buy rating, following revised estimates for future earnings and margins. The firm anticipates flat EBITDA growth for 2026 but suggests potential reacceleration in 2027 with the launch of new branded products.
BofA had previously reduced Teva’s price target from $26.00 to $23.00, citing conservative margin expectations and adjustments to operating expenses. Despite these changes, BofA remains optimistic about Teva’s pipeline and future revenue potential. These developments reflect the evolving landscape for Teva as it navigates market challenges and opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.